ResApp Health Ltd - Strategic SWOT Analysis Review

ResApp Health Ltd - Strategic SWOT Analysis Review

- provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services.

This up-to-the-minute company report will help you to formulate strategies to drive your business by enabling you to understand your partners, customers and competitors better.

Scope

• Business description – A detailed description of the company’s operations and business divisions.
• Corporate strategy – GlobalData’s summarization of the company’s business strategy.
• SWOT analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
• Company history – Progression of key events associated with the company.
• Major products and services – A list of major products, services and brands of the company.
• Key competitors – A list of key competitors to the company.
• Key employees – A list of the key executives of the company.
• Executive biographies – A brief summary of the executives’ employment history.
• Key operational heads – A list of personnel heading key departments/functions.
• Important locations and subsidiaries – A list of key locations and subsidiaries of the company, including contact details.

Highlights

ResApp Health Ltd (ResApp), a subsidiary of Pfizer Australia Holdings Pty Ltd, is a digital health company that develops smartphone applications for the diagnosis and management of respiratory disease. It's digital healthcare solutions assist doctors and patients to diagnose and manage respiratory diseases. The company’s products include SleepCheck, an at-home sleep apnoea screening app for customers to self-assess their risk of sleep apnoea; and ResAppDx-EU, a smartphone based acute respiratory disease diagnostic test for respiratory disease in adults and children. ResApp has license from The University of Queensland for technology that uses sound to diagnose respiratory diseases including upper respiratory tract infections, bronchitis, pneumonia, asthma and chronic obstructive pulmonary disease (COPD). Markets for ResApp’s technology include emergency department and regular clinic use by healthcare providers, at-home use by consumers and telehealth use through partnerships with telehealth service providers. ResApp is headquartered in Brisbane, Queensland, Australia.

ResApp Health Ltd Key Recent Developments

Dec 20,2021: ResApp receives $818,826 in R&D tax incentive refund
Dec 08,2021: ResApp establishes COVID-19 Scientific Advisory Board
Sep 14,2021: ResApp receives advanced and overseas R&D finding
May 18,2021: Brian Leedman reappointed as Executive Director

Reasons to Buy

• Gain key insights into the company for academic or business research purposes. Key elements such as SWOT analysis and corporate strategy are incorporated in the profile to assist your academic or business research needs.
• Identify potential customers and suppliers with this report’s analysis of the company’s business structure, operations, major products and services and business strategy.
• Understand and respond to your competitors’ business structure and strategies with GlobalData’s detailed SWOT analysis. In this, the company’s core strengths, weaknesses, opportunities and threats are analyzed, providing you with an up to date objective view of the company.
• Examine potential investment and acquisition targets with this report’s detailed insight into the company’s strategic, business and operational performance.

Note:Some sections may be missing if data is unavailable for the company.